Intuitive Surgical (NASDAQ:ISRG) Stock Lifted to “Buy” by Erste Group Bank

Intuitive Surgical (NASDAQ:ISRG) was upgraded by stock analysts at Erste Group Bank from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Briefing.com reports.

Several other analysts have also commented on ISRG. Oppenheimer upgraded shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price target on the stock in a research report on Wednesday, August 12th. BTIG Research dropped their price objective on Intuitive Surgical from $469.00 to $454.00 and set a “buy” rating for the company in a report on Monday, October 12th. Sanford C. Bernstein reissued an “outperform” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. Leerink Partners cut their price objective on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating on the stock in a report on Friday, July 17th. Finally, Stifel Nicolaus reduced their price objective on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. Twenty-five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $498.72.

Intuitive Surgical Stock Up 1.1%

NASDAQ:ISRG opened at $438.00 on Wednesday. Intuitive Surgical has a 52-week low of $328.57 and a 52-week high of $603.88. The company has a market capitalization of $154.74 billion, a PE ratio of 50.17, a P/E/G ratio of 3.27 and a beta of 1.46. The stock’s 50 day moving average price is $392.96 and its 200 day moving average price is $409.06.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.35. The firm had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company’s revenue for the quarter was up 21.7% on a year-over-year basis. During the same period last year, the company earned $2.40 earnings per share. As a group, sell-side analysts anticipate that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Fredrik Widman sold 1,089 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president owned 1,026 shares of the company’s stock, valued at $384,175.44. This trade represents a 51.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 72 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $393.10, for a total transaction of $28,303.20. Following the sale, the director owned 179 shares of the company’s stock, valued at $70,364.90. The trade was a 28.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after buying an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $1,335,753,000. Amundi lifted its position in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Intuitive Surgical by 95.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after buying an additional 1,027,475 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Intuitive Surgical by 13.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock worth $804,431,000 after buying an additional 211,237 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
• Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
• Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.